Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 May 6;2(5):e250–e262. doi: 10.1016/S2666-7568(21)00062-3

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license

Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

PMC Copyright notice

Number of laboratory-confirmed RTIs in each treatment group caused by specific viruses in the phase 2b and phase 3 trials

Part A shows the number of patients with laboratory-confirmed RTIs of any severity caused by specific viruses in the RTB101 group (blue bars) versus the placebo group (grey bars) in the phase 2b, phase 3, and combined phase 2b and phase 3 trials (A). Part B shows the number of patients with laboratory-confirmed RTIs with severe symptoms caused by specific viruses in the RTB101 group (blue bars) versus the placebo group (grey bars) in the phase 2b, phase 3, and combined phase 2b and phase 3 trials. RTI=respiratory tract infection.